Secukinumab shown to work in 9/15 (67%) of refractory Behçet’s patients (mucosal and articular dz) by 3 mos - Retrospective study looked a complete or partial responders. #s increased to 86.7% at 6 months. Doses: either 150 or 300 mg qmonth https://t.co/a3Fp3qdbkG